Revvity company profile
Company profile
Revvity has 11,000 employees and is headquartered in Waltham, United States.
Known for its EUROIMMUN, IDS-iSYS and DELFIA diagnostic assays, BioLegend antibodies and Cellometer cell counters, Revvity offers instruments, reagents, software and services for health sciences. Its diagnostics range covers early detection screening, including pregnancy and early childhood tests for genetic disorders such as Down syndrome and hypothyroidism, as well as infectious disease testing. Research tools support genomic workflows, oncology, immunodiagnostics and drug discovery, with products such as Dharmacon reagents and AlphaLISA assays. Customers include pharmaceutical and biotechnology companies, laboratories, public health authorities and government agencies.
In the fiscal year ended December 28, 2025, revenue was $2.9 billion, up 3.7% from the previous year, and net income reached $241.2 million. The company employs 11,000 people and is headquartered in Waltham, Massachusetts. Founded in 1937, it operated as PerkinElmer, Inc. until it changed its name to Revvity, Inc. in April 2023. The United States accounted for 39.4% of revenue in the same year, followed by China at 14.9%, Germany at 6.2% and the United Kingdom at 4.4%, with other international markets making up 35.0%.
Company facts
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Headquarters
- 77 4th Avenue, 02451, Waltham
- Employees
- 11,000
- Chief executive
- Prahlad Singh
- Founded
- 1937
- Fiscal year
- January - December
- Listing
- RVTY · NYSE
- Indices
- S&P 500
- Currency
- USD
- ISIN
- US7140461093
- Website
- revvity.com
Revvity and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| RevvityRVTY | United States | $16.21B | 11,000 | 16.7% | 64.5 |
| Medpace HoldingsMEDP | United States | $17.08B | 6,600 | 21.4% | 33.9 |
| Charles River Laboratories InternationalCRL | United States | $15.06B | 18,300 | 14.3% | 341.7 |
| ICON PublicICLR | United States | $13.99B | 40,250 | 2.7% | 74.7 |
| Guardant HealthGH | United States | $19.73B | 2,490 | -39.4% | — |
| Quest DiagnosticsDGX | United States | $28.42B | 60,000 | 14.9% | 25.7 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
